Clene Inc.
CNM-Au8
amyotrophic lateral sclerosis (ALS)
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for CNM-Au8 in amyotrophic lateral sclerosis (ALS) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Following the completion of multiple Phase 2 clinical trials and continued support of open label expanded access programs, we have now treated over 800 patients with CNM-Au8, our orally administered nanocrystal suspension, encompassing one ”